Latest news
25 items- PRTCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of DirectorsTCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors. Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops po
- 13D/GSEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)SC 13G/A - Kindred Biosciences, Inc. (0001561743) (Subject)
- INSIDERSEC Form 4 filed by Park West Asset Management Llc4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- SECSEC Form 15-12B filed by Kindred Biosciences, Inc.15-12B - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECSEC Form EFFECT filed by Kindred Biosciences, Inc.EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer)
- 13D/GSEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)SC 13D/A - Kindred Biosciences, Inc. (0001561743) (Subject)
- INSIDERSEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4: Bevers Denise returned $1,348,974 worth of Common Stock to the company (145,835 units at $9.25), closing all direct ownership in the company4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4: Zhan Hangjun returned $594,830 worth of Common Stock to the company (64,306 units at $9.25), closing all direct ownership in the company4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4 filed by Veszpremi Ervin4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4: Townsend Raymond returned $230,584 worth of Common Stock to the company (24,928 units at $9.25), closing all direct ownership in the company4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4 filed by Montgomery Herbert D4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4 filed by Mccracken Joseph S4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4 filed by Lien Lyndon4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- INSIDERSEC Form 4 filed by Liu Nanxi4 - Kindred Biosciences, Inc. (0001561743) (Issuer)
- SECSEC Form S-8 POS filed by Kindred Biosciences, Inc.S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECSEC Form S-8 POS filed by Kindred Biosciences, Inc.S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECSEC Form S-8 POS filed by Kindred Biosciences, Inc.S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECSEC Form S-8 POS filed by Kindred Biosciences, Inc.S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECSEC Form S-8 POS filed by Kindred Biosciences, Inc.S-8 POS - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECSEC Form POS AM filed by Kindred Biosciences, Inc.POS AM - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECKindred Biosciences, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Kindred Biosciences, Inc. (0001561743) (Filer)
- SECSEC Form 25-NSE filed by Kindred Biosciences, Inc.25-NSE - Kindred Biosciences, Inc. (0001561743) (Subject)
- SECKindred Biosciences, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Kindred Biosciences, Inc. (0001561743) (Filer)
KIN FAQ
6 questionsWhat does Kindred Biosciences, Inc. do?
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in...Where does KIN stock trade?
Kindred Biosciences, Inc. (KIN) is listed on NASDAQ.What sector and industry is KIN in?
Kindred Biosciences, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Kindred Biosciences, Inc. go public?
Kindred Biosciences, Inc. (KIN) completed its IPO in 2013.What companies are similar to KIN?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare KIN side-by-side with any of them on Quantisnow.How can I track KIN on Quantisnow?
Quantisnow aggregates Kindred Biosciences, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KIN to receive live email and push alerts on every new disclosure.